Tovorafenib
day one biopharmaceutical
['tovorafenib', '$dawn']
piper sandler $dawn overweight/$45 tovorafenib's updated data at asco, should put to rest some debate on response criteria and the filing strategy. thinks orr per rano-lgg was at the high end of expectations heading into this update. while there may be some continued $eras 